InvestSMART

Racura Oncology Ltd (ASX: RAC) - Share Price

Current share price for RAC : $2.060 0.01 (0.48%)+

Racura Oncology (RAC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Phase 3 clinical biopharmaceutical company with a mission to be at the heart of cancer care.

RAC General Information +

ASX Code RAC
Website http://www.racuraoncology.com
Industry/Sector Biotechnology
Market Cap ($M) 403
RAC Share Price $2.060
Day High $2.120
Day Low $2.040
Last Close $2.070
RAC Share Price Movement $0.01 ( 0.48% )
Prices as at 16:40, 23 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Racura Oncology Ltd (RAC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Racura Oncology Ltd (RAC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Racura Oncology Ltd (RAC) price-sensitive announcements

RAC - Appendix 4E & Annual Report
Racura Oncology Ltd, formerly known as Race Oncology Limited, reported significant advance
Racura Oncology Ltd (RAC)
25 Aug 2026 | 5:21 PM
RAC - First HARNESS-1 Patient Safely Treated with RC220
Racura Oncology Ltd has announced the successful treatment of the first patient in its HAR
Racura Oncology Ltd (RAC)
29 Jul 2026 | 9:04 AM
RAC - June 2026 Quarterly Activities Report and Appendix 4C
Racura Oncology Ltd reported significant clinical and corporate advancements in its June 2
Racura Oncology Ltd (RAC)
28 Jul 2026 | 9:12 AM
RAC - Bellberry Ethics Approval Activates New HARNESS Trial Sites
Racura Oncology Ltd announced the Bellberry Human Research Ethics Committee (HREC) approva
Racura Oncology Ltd (RAC)
3 Jul 2026 | 8:46 AM

Racura Oncology Ltd (RAC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
 Health Care $404 Appendix 3Y - Dr Daniel Tillett 23 Sep 2026 8:39AM $2.070 $2.060 fallen by 0.48%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
 Health Care $404 RC220 MYC-silencing data to be presented FCS 26 conference 8 Sep 2026 9:15AM $2.130 $2.060 fallen by 3.29%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
 Health Care $404 Racura Oncology Adelaide Investor Briefing 4 Sep 2026 9:57AM $2.140 $2.060 fallen by 3.74%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
 Health Care $404 Notification regarding unquoted securities - RAC 1 Sep 2026 1:15PM $2.210 $2.060 fallen by 6.79%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
 Health Care $404 CPACS Trial Opens for RC220 Patient Enrolment in Korea 1 Sep 2026 8:58AM $2.130 $2.060 fallen by 3.29%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
 Health Care $404 Corporate Governance Statement 25 Aug 2026 5:22PM $2.120 $2.060 fallen by 2.83%

RAC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$9.95 -$5.60 99.60% 0.00 0.00 0.00% 0.0%
2025A -$4.79 -$2.80 -66.90% 0.00 0.00 0.00% 0.0%
2024A -$13.82 -$8.40 36.10% 0.00 0.00 0.00% 0.0%

RAC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $86,725M 0.7309 -0.4446 0.0545 11.1960 20.1602 19.1175 2.35% 2.30% 2.37%
Mesoblast Limited (MSB) $2,805M -0.4380 0.0000 0.0000 0.0000 0.0000 342.8571 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $2,833M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Racura Oncology Ltd (RAC) $406M 0.9964 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,707M -1.3893 0.0000 -0.2780 0.0000 185.9358 257.5153 0.00% 0.00% 0.00%

RAC Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 11.10 0.00
Market 0.31 13.80 1.17 0.80
Sector 0.68 30.60 2.72 2.46

RAC Directors

Name Position Start Date
Dr Daniel Tillett Chief Executive Officer, Managing Director 1 Sep 2024
Dr Peter (Pete) Smith Executive Director, Executive Chairman 28 Jun 2023
Dr Megan Baldwin Non-Executive Director 1 Jan 2025
Dr Serge Scrofani Non-Executive Director 1 Sep 2024

Racura Oncology Ltd (RAC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
5 Jun 2026 SCROFANI, Serge Buy Indirect Shares 11,285 $2.692 $30,375.290
28 May 2026 TILLETT, Daniel Exercise Options 400,000 $1.250 $500,000.000
28 May 2026 TILLETT, Daniel Buy Direct Shares 400,000 $1.250 $500,000.000

See all changes in directors' interest & trades for Racura Oncology Ltd (RAC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAC Management

Name Position
Peter Webse Company Secretary

RAC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Racura Oncology Ltd (RAC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
20,269,351 (10.34%) Daniel Tillett

RAC Calendar of Events

Date Event
24 August 2027 Report (Annual)
24 August 2027 Report (Prelim)
26 February 2027 Report (Interim)
23 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.